Prosecution Insights
Prosecution Insights
10 pending office actions • 8 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (10%) |
| §101 + other | 2 (20%) |
| §103 only | 1 (10%) |
| §112 only | 3 (30%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 2 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANGHERA, STEVEN G.S. | 1 | 30.0% | +29.1% |
| HU, ANN M | 1 | 67.8% | +21.4% |
| LANKFORD JR, LEON B | 1 | 69.9% | +31.3% |
| DENT, ALANA HARRIS | 1 | 44.3% | +32.1% |
| SCHWECHTER, BRANDON ROSS | 1 | — | — |
| MEJIAS, SAMANTHA LEE | 1 | 50.0% | +60.0% |
| REYNOLDS, FRED H | 1 | 33.1% | +39.0% |
| ISMAIL, REHANA | 1 | 77.3% | +32.8% |
| BUCHANAN, BAILEY CHEYENNE | 1 | 47.6% | +50.0% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 30.0% | +38.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692301 | SAMPLING INTERVAL ADJUSTED CLASSIFICATION TOOL | SANGHERA, STEVEN G.S. | — |
| 18687769 | PERIVASCULAR IMPLANT | HU, ANN M | — |
| 18552115 | ANTIGEN REACTIVE T-CELL RECEPTORS | SCHWECHTER, BRANDON ROSS | — |
| 17623556 | CHEMICAL INHIBITORS OF ID PROTEINS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | ISMAIL, REHANA | — |
| 17600531 | METHOD OF CLASSIFYING A SAMPLE BASED ON DETERMINATION OF FGFR | BUCHANAN, BAILEY CHEYENNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578142 | Xenon Gas for Use in the Treatment of Gliomas | DENT, ALANA HARRIS | 52d overdue |
| 17051123 | MODIFIED AAV CAPSID POLYPEPTIDES FOR TREATMENT OF MUSCULAR DISEASES | KONOPELSKI SNAVEL, SARA ELIZABETH | 35d |
| 18692301 | SAMPLING INTERVAL ADJUSTED CLASSIFICATION TOOL | SANGHERA, STEVEN G.S. | — |
| 18687769 | PERIVASCULAR IMPLANT | HU, ANN M | — |
| 18293313 | RNAYLATION | LANKFORD JR, LEON B | — |
| 18258631 | BISPIDINE DERIVATIVES AND THE USE THEREOF | MEJIAS, SAMANTHA LEE | — |
| 17767880 | CONJUGATE COMPOUNDS FOR PREVENTING AND/OR TREATING HBV AND/OR HDV INFECTIONS, LIVER DISEASES AND FOR TARGETING NTCP | REYNOLDS, FRED H | — |
| 17623556 | CHEMICAL INHIBITORS OF ID PROTEINS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | ISMAIL, REHANA | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 3684 | 1 |
| 1657 | 1 |
| 1643 | 1 |
| 1681 | 1 |
| 1618 | 1 |
| 1625 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692301 | SAMPLING INTERVAL ADJUSTED CLASSIFICATION TOOL | SANGHERA, STEVEN G.S. | 3684 | §101 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18687769 | PERIVASCULAR IMPLANT | HU, ANN M | — | §101§102§103§112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18293313 | RNAYLATION | LANKFORD JR, LEON B | 1657 | §112 | Non-Final OA | — | Pending | Jan 29, 2024 |
| 18578142 | Xenon Gas for Use in the Treatment of Gliomas | DENT, ALANA HARRIS | 1643 | §103 | Final Rejection | 52d overdue | Pending | Jan 10, 2024 |
| 18552115 | ANTIGEN REACTIVE T-CELL RECEPTORS | SCHWECHTER, BRANDON ROSS | 1681 | §101§102§112 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18258631 | BISPIDINE DERIVATIVES AND THE USE THEREOF | MEJIAS, SAMANTHA LEE | 1618 | §112 | Non-Final OA | — | Pending | Jun 21, 2023 |
| 17767880 | CONJUGATE COMPOUNDS FOR PREVENTING AND/OR TREATING HBV AND/OR HDV INFECTIONS, LIVER DISEASES AND FOR TARGETING NTCP | REYNOLDS, FRED H | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Apr 09, 2022 |
| 17623556 | CHEMICAL INHIBITORS OF ID PROTEINS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | ISMAIL, REHANA | 1625 | §103§112 | Non-Final OA | — | Pending | Dec 28, 2021 |
| 17600531 | METHOD OF CLASSIFYING A SAMPLE BASED ON DETERMINATION OF FGFR | BUCHANAN, BAILEY CHEYENNE | 1682 | §103§112 | Final Rejection | — | Pending | Sep 30, 2021 |
| 17051123 | MODIFIED AAV CAPSID POLYPEPTIDES FOR TREATMENT OF MUSCULAR DISEASES | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §112 | Non-Final OA | 35d | Pending | Oct 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial